Overview
- A reconstituted FDA Pharmacy Compounding Advisory Committee voted to add BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax to the Section 503A bulks list after its July 23–24 meeting.
- Career FDA scientists had recommended against listing the peptides because many lack consistent chemical definitions, reference standards, and robust human safety or efficacy data.
- Patient‑safety groups and bioethicists warned of risks such as immune reactions, contamination, and theoretical cancer concerns for epitalon, and they flagged apparent conflicts of interest among newly added panel members.
- If the FDA accepts the advice, state‑licensed compounders could legally prepare these peptides for prescriptions but those products would not be FDA‑approved and the agency cannot presently force mandatory adverse‑event reporting from state pharmacies.
- Experts say the move could shift patients away from unregulated online suppliers but could also reduce incentives for formal clinical trials and invite legal and regulatory challenges during any notice‑and‑comment rulemaking.